Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Aquestive Therapeutics ( (AQST) ).
On March 3, 2026, Aquestive Therapeutics amended its existing revenue-sharing Purchase and Sale Agreement with RTW Investments to extend the marketing approval deadline for its lead product candidate Anaphylm to June 30, 2027, easing timing pressure around regulatory milestones. In connection with the amendment, RTW funds received a warrant to buy up to 375,000 Aquestive common shares at $4.00 per share through March 3, 2029, and affiliated RTW funds committed to purchase at least $5 million of common stock within 90 days, bolstering the company’s balance sheet as it works toward resubmitting Anaphylm’s NDA and preparing for a potential launch.
The company also reported fourth-quarter and full-year 2025 results on March 4, 2026, noting that it met 2025 guidance for revenue and non-GAAP adjusted EBITDA loss excluding one-time items and expects to end 2026 with $70 million in cash and equivalents. Operationally, Aquestive is addressing a January 30, 2026 Complete Response Letter from the FDA for Anaphylm with new human factors and PK studies ahead of a planned NDA resubmission in the third quarter of 2026, continued regulatory work in Canada and the EU, ongoing development of AQST-108 following completion of Phase 1 dosing, and stable manufacturing and royalty revenue streams that help support its allergy and neurology-focused growth strategy.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Overall score is pressured primarily by weak financial performance (losses, cash burn, and negative equity). Technical indicators also lean bearish (below key moving averages with negative MACD). Valuation is constrained by unprofitability and no dividend, partially offset by a relatively better earnings-call outlook supported by financing and commercialization planning.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc., based in Warren, N.J., is a pharmaceutical company focused on advancing medicines through proprietary oral and film-based delivery technologies. The company develops and manufactures non-invasive treatments for conditions such as severe allergies, epilepsy, ADHD and other CNS and specialty indications, and also supplies products to partners including Indivior, Assertio, Hypera and Zambon under licensing and manufacturing collaborations.
Its commercial portfolio includes sublingual and oral film products such as Suboxone, Sympazan, Ondif and Emylif, while its pipeline is led by Anaphylm, a sublingual epinephrine film for severe allergic reactions, and AQST-108, a topical gel candidate for alopecia areata and other dermatologic uses. Aquestive generates revenue from both manufacturing volumes and royalties, and positions itself as a U.S.-based manufacturer with supply chains largely insulated from recent and proposed tariff disruptions.
Average Trading Volume: 4,924,527
Technical Sentiment Signal: Sell
Current Market Cap: $502.7M
Find detailed analytics on AQST stock on TipRanks’ Stock Analysis page.